en.unionpedia.org

Brilaroxazine, the Glossary

Brilaroxazine (developmental code name RP5063), also known as oxaripiprazole, is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of neuropsychiatric and inflammatory disorders.^[1]

74 relations: Adverse event, Akathisia, Alpha-1B adrenergic receptor, Alpha-2 adrenergic receptor, Alpha-4 beta-2 nicotinic receptor, Alzheimer's disease, Aripiprazole, Attention deficit hyperactivity disorder, Atypical antipsychotic, Autism, Bipolar disorder, Brexpiprazole, Cariprazine, Chemical structure, Clinical global impression, Clinical trial, CYP2D6, CYP3A4, Dopamine, Dopamine receptor D1, Dopamine receptor D2, Dopamine receptor D3, Dopamine receptor D4, Dopamine receptor D5, Dopamine transporter, Extrapyramidal symptoms, High-density lipoprotein, Histamine H1 receptor, Hydrochloride, Idiopathic pulmonary fibrosis, Inflammation, Investigational New Drug, Ligand (biochemistry), List of investigational antidepressants, List of investigational antipsychotics, Liver, Low-density lipoprotein, Major depressive disorder, Medication discontinuation, Methylene group, Muscarinic acetylcholine receptor, Neuropsychiatry, Neurotransmitter, New Drug Application, Norepinephrine transporter, Oral administration, Orphan drug, Oxazines, Oxygen, Parkinson's disease, ... Expand index (24 more) »
5-HT1A agonists
5-HT2A agonists
5-HT2B antagonists
5-HT2C antagonists
5-HT6 antagonists
5-HT7 antagonists
Atypical antipsychotics
Benzoxazines
D2-receptor agonists
Experimental drugs developed for schizophrenia
Serotonin reuptake inhibitors

Adverse event

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

See Brilaroxazine and Adverse event

Akathisia

Akathisia (IPA: /æ.kə.ˈθɪ.si.ə/) is a movement disorder characterized by a subjective feeling of inner restlessness accompanied by mental distress and an inability to sit still.

See Brilaroxazine and Akathisia

Alpha-1B adrenergic receptor

The alpha-1B adrenergic receptor (α1B-adrenoreceptor), also known as ADRA1B, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it.

See Brilaroxazine and Alpha-1B adrenergic receptor

Alpha-2 adrenergic receptor

The alpha-2 (α2) adrenergic receptor (or adrenoceptor) is a G protein-coupled receptor (GPCR) associated with the Gi heterotrimeric G-protein.

See Brilaroxazine and Alpha-2 adrenergic receptor

Alpha-4 beta-2 nicotinic receptor

The alpha-4 beta-2 nicotinic receptor, also known as the α4β2 receptor, is a type of nicotinic acetylcholine receptor implicated in learning, consisting of α4 and β2 subunits.

See Brilaroxazine and Alpha-4 beta-2 nicotinic receptor

Alzheimer's disease

Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens, and is the cause of 60–70% of cases of dementia.

See Brilaroxazine and Alzheimer's disease

Aripiprazole

Aripiprazole, sold under the brand names Abilify and Aristada, among others, is an atypical antipsychotic. It is primarily used in the treatment of schizophrenia and bipolar disorder; other uses include as an add-on treatment in major depressive disorder and obsessive compulsive disorder (OCD), tic disorders, and irritability associated with autism. Brilaroxazine and Aripiprazole are 5-HT2B antagonists, 5-HT7 antagonists, atypical antipsychotics and d2-receptor agonists.

See Brilaroxazine and Aripiprazole

Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterised by executive dysfunction occasioning symptoms of inattention, hyperactivity, impulsivity and emotional dysregulation that are excessive and pervasive, impairing in multiple contexts, and otherwise age-inappropriate.

See Brilaroxazine and Attention deficit hyperactivity disorder

Atypical antipsychotic

The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), are a group of antipsychotic drugs (antipsychotic drugs in general are also known as tranquilizers and neuroleptics, although the latter is usually reserved for the typical antipsychotics) largely introduced after the 1970s and used to treat psychiatric conditions. Brilaroxazine and atypical antipsychotic are atypical antipsychotics.

See Brilaroxazine and Atypical antipsychotic

Autism

Autism, also called autism spectrum disorder (ASD) or autism spectrum condition (ASC), is a neurodevelopmental disorder characterised by symptoms of deficient reciprocal social communication and the presence of restricted, repetitive and inflexible patterns of behavior that are impairing in multiple contexts and excessive or atypical to be developmentally and socioculturally inappropriate.

See Brilaroxazine and Autism

Bipolar disorder

Bipolar disorder, previously known as manic depression, is a mental disorder characterized by periods of depression and periods of abnormally elevated mood that each last from days to weeks.

See Brilaroxazine and Bipolar disorder

Brexpiprazole

Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease. Brilaroxazine and Brexpiprazole are 5-HT1A agonists, 5-HT2B antagonists, 5-HT7 antagonists, atypical antipsychotics, d2-receptor agonists and Piperazines.

See Brilaroxazine and Brexpiprazole

Cariprazine

Cariprazine, sold under the brand name Vraylar among others, is an atypical antipsychotic developed by Gedeon Richter, which is used in the treatment of schizophrenia, bipolar mania, bipolar depression, and major depressive disorder. Brilaroxazine and Cariprazine are atypical antipsychotics.

See Brilaroxazine and Cariprazine

Chemical structure

A chemical structure of a molecule is a spatial arrangement of its atoms and their chemical bonds.

See Brilaroxazine and Chemical structure

Clinical global impression

The clinical global impression (CGI) rating scales are measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders.

See Brilaroxazine and Clinical global impression

Clinical trial

Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.

See Brilaroxazine and Clinical trial

CYP2D6

Cytochrome P450 2D6 (CYP2D6) is an enzyme that in humans is encoded by the CYP2D6 gene.

See Brilaroxazine and CYP2D6

CYP3A4

Cytochrome P450 3A4 (abbreviated CYP3A4) is an important enzyme in the body, mainly found in the liver and in the intestine, which in humans is encoded by CYP3A4 gene.

See Brilaroxazine and CYP3A4

Dopamine

Dopamine (DA, a contraction of 3,4-dihydroxyphenethylamine) is a neuromodulatory molecule that plays several important roles in cells. Brilaroxazine and Dopamine are dopamine agonists.

See Brilaroxazine and Dopamine

Dopamine receptor D1

Dopamine receptor D1, also known as DRD1.

See Brilaroxazine and Dopamine receptor D1

Dopamine receptor D2

Dopamine receptor D2, also known as D2R, is a protein that, in humans, is encoded by the DRD2 gene.

See Brilaroxazine and Dopamine receptor D2

Dopamine receptor D3

Dopamine receptor D3 is a protein that in humans is encoded by the DRD3 gene.

See Brilaroxazine and Dopamine receptor D3

Dopamine receptor D4

The dopamine receptor D4 is a dopamine D2-like G protein-coupled receptor encoded by the gene on chromosome 11 at 11p15.5.

See Brilaroxazine and Dopamine receptor D4

Dopamine receptor D5

Dopamine receptor D5, also known as D1BR, is a protein that in humans is encoded by the DRD5 gene.

See Brilaroxazine and Dopamine receptor D5

Dopamine transporter

The dopamine transporter (DAT, also sodium-dependent dopamine transporter) is a membrane-spanning protein coded for in humans by the SLC6A3 gene (also known as DAT1), that pumps the neurotransmitter dopamine out of the synaptic cleft back into cytosol.

See Brilaroxazine and Dopamine transporter

Extrapyramidal symptoms (EPS) are symptoms that are archetypically associated with the extrapyramidal system of the brain's cerebral cortex.

See Brilaroxazine and Extrapyramidal symptoms

High-density lipoprotein

High-density lipoprotein (HDL) is one of the five major groups of lipoproteins.

See Brilaroxazine and High-density lipoprotein

Histamine H1 receptor

The H1 receptor is a histamine receptor belonging to the family of rhodopsin-like G-protein-coupled receptors.

See Brilaroxazine and Histamine H1 receptor

Hydrochloride

In chemistry, a hydrochloride is an acid salt resulting, or regarded as resulting, from the reaction of hydrochloric acid with an organic base (e.g. an amine).

See Brilaroxazine and Hydrochloride

Idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) synonymous with cryptogenic fibrosing alveolitis is a rare, progressive illness of the respiratory system, characterized by the thickening and stiffening of lung tissue, associated with the formation of scar tissue.

See Brilaroxazine and Idiopathic pulmonary fibrosis

Inflammation

Inflammation (from inflammatio) is part of the biological response of body tissues to harmful stimuli, such as pathogens, damaged cells, or irritants.

See Brilaroxazine and Inflammation

Investigational New Drug

The United States Food and Drug Administration's Investigational New Drug (IND) program is the means by which a pharmaceutical company obtains permission to start human clinical trials and to ship an experimental drug across state lines (usually to clinical investigators) before a marketing application for the drug has been approved.

See Brilaroxazine and Investigational New Drug

Ligand (biochemistry)

In biochemistry and pharmacology, a ligand is a substance that forms a complex with a biomolecule to serve a biological purpose.

See Brilaroxazine and Ligand (biochemistry)

List of investigational antidepressants

This is a list of investigational antidepressants, or antidepressants that are currently under development for clinical use in the treatment of mood disorders but are not yet approved. Brilaroxazine and list of investigational antidepressants are experimental antidepressants.

See Brilaroxazine and List of investigational antidepressants

List of investigational antipsychotics

This is a list of investigational antipsychotics, or antipsychotics that are currently under development for clinical use but are not yet approved.

See Brilaroxazine and List of investigational antipsychotics

Liver

The liver is a major metabolic organ exclusively found in vertebrate animals, which performs many essential biological functions such as detoxification of the organism, and the synthesis of proteins and various other biochemicals necessary for digestion and growth.

See Brilaroxazine and Liver

Low-density lipoprotein

Low-density lipoprotein (LDL) is one of the five major groups of lipoprotein that transport all fat molecules around the body in extracellular water.

See Brilaroxazine and Low-density lipoprotein

Major depressive disorder

Major depressive disorder (MDD), also known as clinical depression, is a mental disorder characterized by at least two weeks of pervasive low mood, low self-esteem, and loss of interest or pleasure in normally enjoyable activities.

See Brilaroxazine and Major depressive disorder

Medication discontinuation

Medication discontinuation is the ceasing of a medication treatment for a patient by either the clinician or the patient themself.

See Brilaroxazine and Medication discontinuation

Methylene group

A methylene group is any part of a molecule that consists of two hydrogen atoms bound to a carbon atom, which is connected to the remainder of the molecule by two single bonds.

See Brilaroxazine and Methylene group

Muscarinic acetylcholine receptor

Muscarinic acetylcholine receptors, or mAChRs, are acetylcholine receptors that form G protein-coupled receptor complexes in the cell membranes of certain neurons and other cells.

See Brilaroxazine and Muscarinic acetylcholine receptor

Neuropsychiatry

Neuropsychiatry is a branch of medicine that deals with psychiatry as it relates to neurology, in an effort to understand and attribute behavior to the interaction of neurobiology and social psychology factors.

See Brilaroxazine and Neuropsychiatry

Neurotransmitter

A neurotransmitter is a signaling molecule secreted by a neuron to affect another cell across a synapse.

See Brilaroxazine and Neurotransmitter

New Drug Application

The Food and Drug Administration's (FDA) New Drug Application (NDA) is the vehicle in the United States through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing.

See Brilaroxazine and New Drug Application

Norepinephrine transporter

The norepinephrine transporter (NET), also known as noradrenaline transporter (NAT), is a protein that in humans is encoded by the solute carrier family 6 member 2 (SLC6A2) gene.

See Brilaroxazine and Norepinephrine transporter

Oral administration

| name.

See Brilaroxazine and Oral administration

Orphan drug

An orphan drug is a pharmaceutical agent that is developed to treat certain rare medical conditions.

See Brilaroxazine and Orphan drug

Oxazines

Oxazines are heterocyclic organic compounds containing one oxygen and one nitrogen atom in a cyclohexa-1,4-diene ring (a doubly unsaturated six-membered ring).

See Brilaroxazine and Oxazines

Oxygen

Oxygen is a chemical element; it has symbol O and atomic number 8.

See Brilaroxazine and Oxygen

Parkinson's disease

Parkinson's disease (PD), or simply Parkinson's, is a long-term neurodegenerative disease of mainly the central nervous system that affects both the motor and non-motor systems of the body.

See Brilaroxazine and Parkinson's disease

Partial agonist

In pharmacology, partial agonists are drugs that bind to and activate a given receptor, but have only partial efficacy at the receptor relative to a full agonist.

See Brilaroxazine and Partial agonist

Pharmacodynamics

Pharmacodynamics (PD) is the study of the biochemical and physiologic effects of drugs (especially pharmaceutical drugs).

See Brilaroxazine and Pharmacodynamics

Pharmacophore

An example of a pharmacophore model In medicinal chemistry and molecular biology, a pharmacophore is an abstract description of molecular features that are necessary for molecular recognition of a ligand by a biological macromolecule.

See Brilaroxazine and Pharmacophore

Positive and Negative Syndrome Scale

The Positive and Negative Syndrome Scale (PANSS) is a medical scale used for measuring symptom severity of patients with schizophrenia.

See Brilaroxazine and Positive and Negative Syndrome Scale

Psoriasis

Psoriasis is a long-lasting, noncontagious autoimmune disease characterized by patches of abnormal skin.

See Brilaroxazine and Psoriasis

Psychomotor agitation

Psychomotor agitation is a symptom in various disorders and health conditions.

See Brilaroxazine and Psychomotor agitation

Psychosis

Psychosis is a condition of the mind or psyche that results in difficulties determining what is real and what is not real.

See Brilaroxazine and Psychosis

Pulmonary hypertension

Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure in the arteries of the lungs.

See Brilaroxazine and Pulmonary hypertension

Quinolone

Quinolone may refer to.

See Brilaroxazine and Quinolone

Receptor antagonist

A receptor antagonist is a type of receptor ligand or drug that blocks or dampens a biological response by binding to and blocking a receptor rather than activating it like an agonist.

See Brilaroxazine and Receptor antagonist

Ring (chemistry)

In chemistry, a ring is an ambiguous term referring either to a simple cycle of atoms and bonds in a molecule or to a connected set of atoms and bonds in which every atom and bond is a member of a cycle (also called a ring system).

See Brilaroxazine and Ring (chemistry)

Schizophrenia

Schizophrenia is a mental disorder characterized by reoccurring episodes of psychosis that are correlated with a general misperception of reality.

See Brilaroxazine and Schizophrenia

Serotonin

Serotonin or 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter.

See Brilaroxazine and Serotonin

Serotonin transporter

The serotonin transporter (SERT or 5-HTT) also known as the sodium-dependent serotonin transporter and solute carrier family 6 member 4 is a protein that in humans is encoded by the SLC6A4 gene.

See Brilaroxazine and Serotonin transporter

Somnolence

Somnolence (alternatively sleepiness or drowsiness) is a state of strong desire for sleep, or sleeping for unusually long periods (compare hypersomnia).

See Brilaroxazine and Somnolence

Tic

A tic is a sudden and repetitive motor movement or vocalization that is not rhythmic and involves discrete muscle groups.

See Brilaroxazine and Tic

5-HT1A receptor

The serotonin 1A receptor (or 5-HT1A receptor) is a subtype of serotonin receptors, or 5-HT receptors, that binds serotonin, also known as 5-HT, a neurotransmitter.

See Brilaroxazine and 5-HT1A receptor

5-HT1B receptor

5-hydroxytryptamine receptor 1B also known as the 5-HT1B receptor is a protein that in humans is encoded by the HTR1B gene.

See Brilaroxazine and 5-HT1B receptor

5-HT2A receptor

The 5-HT2A receptor is a subtype of the 5-HT2 receptor that belongs to the serotonin receptor family and is a G protein-coupled receptor (GPCR).

See Brilaroxazine and 5-HT2A receptor

5-HT2B receptor

5-Hydroxytryptamine receptor 2B (5-HT2B) also known as serotonin receptor 2B is a protein that in humans is encoded by the HTR2B gene.

See Brilaroxazine and 5-HT2B receptor

5-HT2C receptor

The 5-HT2C receptor is a subtype of the 5-HT2 receptor that binds the endogenous neurotransmitter serotonin (5-hydroxytryptamine, 5-HT).

See Brilaroxazine and 5-HT2C receptor

5-HT3 receptor

The 5-HT3 receptor belongs to the Cys-loop superfamily of ligand-gated ion channels (LGICs) and therefore differs structurally and functionally from all other 5-HT receptors (5-hydroxytryptamine, or serotonin receptors) which are G protein-coupled receptors.

See Brilaroxazine and 5-HT3 receptor

5-HT6 receptor

The 5HT6 receptor is a subtype of 5HT receptor that binds the endogenous neurotransmitter serotonin (5-hydroxytryptamine, 5HT).

See Brilaroxazine and 5-HT6 receptor

5-HT7 receptor

The 5-HT7 receptor is a member of the GPCR superfamily of cell surface receptors and is activated by the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT).

See Brilaroxazine and 5-HT7 receptor

References

[1] https://en.wikipedia.org/wiki/Brilaroxazine

Also known as C22H25Cl2N3O3, Oxaripiprazole, RP 5000, RP 5063, RP-5000, RP-5063, RP5000, RP5063.

, Partial agonist, Pharmacodynamics, Pharmacophore, Positive and Negative Syndrome Scale, Psoriasis, Psychomotor agitation, Psychosis, Pulmonary hypertension, Quinolone, Receptor antagonist, Ring (chemistry), Schizophrenia, Serotonin, Serotonin transporter, Somnolence, Tic, 5-HT1A receptor, 5-HT1B receptor, 5-HT2A receptor, 5-HT2B receptor, 5-HT2C receptor, 5-HT3 receptor, 5-HT6 receptor, 5-HT7 receptor.

Brilaroxazine, the Glossary

Table of Contents

See also

5-HT1A agonists

5-HT2A agonists

5-HT2B antagonists

5-HT2C antagonists

5-HT6 antagonists

5-HT7 antagonists

Atypical antipsychotics

Benzoxazines

D2-receptor agonists

Experimental drugs developed for schizophrenia

Serotonin reuptake inhibitors

References